PRESS STATEMENTS

02.23.2018

Hospira Issues A Voluntary Nationwide Recall For Labetalol Hydrochloride Injection, USP, Due To The Potential Of Cracked Glass At The Rim Surface Of The Vials

12.11.2017

Pfizer Teams Up with Sickle Cell Disease Community to Launch New Online Platform

11.16.2017

Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets

09.05.2017

Hospira Issues Voluntary Worldwide Recall For Lots of Hydromorphone HCl Injection, USP, CII, (2 mg/mL) 1mg/mL Vial, and Levophed® (Norepinephrine Bitartrate Injection, USP), 4 mg/4 mL (1 mg/mL) Vial, Due to a Lack of Sterility Assurance

08.31.2017

Hospira Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride for Injection, USP, 750 mg/vial Due to The Presence of Particulate Matter Within a Single Vial

06.22.2017

Pfizer Provides Update on Proposed Epoetin Alfa Biosimilar

06.15.2017

Hospira Issues A Voluntary Nationwide Recall For 8.4% Sodium Bicarbonate Injection…

05.30.2017

Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF-06252616)in Duchenne Muscular Dystrophy

04.26.2017

Hospira Issues a Voluntary Nationwide Recall For One Lot Of 25% Dextrose Injection, USP (Infant) Due To The Presence of Particulate Matter

04.13.2017

Pfizer’s Statement On The Misuse Of Our Products In Lethal Injections For Capital Punishment

03.24.2017

Pfizer and the National Newspaper Publishers Association Collaborate to Raise Awareness of Sickle Cell Disease and Need for Improved Patient Care

03.13.2017

European League Against Rheumatism (EULAR) Includes Janus Kinase (JAK) Inhibitors in Updated Recommendations for the Management of RA

11.07.2016

VYNDAQEL® (tafamidis) Receives Approval in Brazil by ANVISA for the Treatment of Transthyretin Familial Amyloid Polyneuropathy

07.05.2016

Pfizer Showcases 12 New Data Presentations On Transthyretin Amyloidosis, Increasing Understanding Of A Rare Disease

04.13.2016

Hospira Issues A Voluntary Recall For One Lot Of 50% Magnesium Sulfate Injection, USP Due To The Presence Of Particulate

03.23.2016

Hospira Issues A Voluntary Recall For One Lot Of Sodium Bicarbonate Injection, USP Due To The Presence Of A Particulate

01.05.2016

HOSPIRA ISSUES A VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF MAGNESIUM SULFATE IN WATER FOR INJECTION DUE TO INCORRECT BARCODE LABELING ON THE PRIMARY CONTAINER

10.28.2015

Pfizer Joins Broad Effort to Observe National Disability Employment Awareness Month

10.13.2015

Pfizer Expands Support for Patients with Gaucher Disease Through New Agreement for ELELYSO

07.17.2015

FDA Accepted For Review Pfizer NDA for ADHD Treatment